Novavax Doubtful About Its Financial Future

The video discusses Novavax's financial struggles, highlighting a recent going concern statement that surprised many. Despite a significant stock rally in 2020, the company faces uncertainty due to delayed COVID vaccine approval and market demand issues. Angelica People's provides insights into these challenges, noting the company's efforts to stabilize. Novavax's financial forecast indicates potential liquidity issues, with uncertainties around revenue and funding. The discussion also covers the broader market demand for COVID vaccines and Novavax's reliance on its COVID vaccine as its main product.

What does the uncertainty in Novavax's cash flow forecast suggest?

What are the implications of the current demand for COVID vaccines on Novavax?